# A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers

> **NCT05178355** · PHASE1 · COMPLETED · sponsor: **KalVista Pharmaceuticals, Ltd.** · enrollment: 108 (actual)

## Conditions studied

- Hereditary Angioedema

## Interventions

- **DRUG:** KVD824
- **DRUG:** Placebo to KVD824

## Key facts

- **NCT ID:** NCT05178355
- **Lead sponsor:** KalVista Pharmaceuticals, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-12
- **Primary completion:** 2019-06-21
- **Final completion:** 2019-06-21
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2022-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178355, "A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05178355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*